Optimizing efficacy of Amphotericin B through nanomodification

References

• AdamsMKwonGS2004Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying and reconstitution of polymeric micellesJ Pharm Pharmaceut Sci7S116
   Google Scholar
• Adler-MooreJPProffittR2002AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experienceJ Antimicrob Ther49Suppl12130
   Web of Science ®Google Scholar
• AgrawalAJAgrawalAPalA2002Superior chemotherapeutic efficacy of Amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamstersJ Drug Target1041511996085
   PubMed Web of Science ®Google Scholar
• AliffTBMaslakPGJurcicJG2003Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericinCancer9710253212569602
   PubMed Web of Science ®Google Scholar
• AmatoVSRabelloARotondo-SilvaA2004Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patientsActa Trop921273215350864
   PubMed Web of Science ®Google Scholar
• BarrattGSchuberF1993Targeting of liposomes with mannose terminated ligandsGregoriadisGLiposome TechnologyVol III2nd edBoca RatonCRC Press Inc199218
   Google Scholar
• BarrettJPVardulakiKAConlonC2003A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulationsClin Ther25129532012867214
   PubMed Web of Science ®Google Scholar
• BochotACouvreurPFattalE2000Intravitreal administration of antisense oligonucleotides: potential of liposomal deliveryProg Retin Eye Res191314710674705
   PubMed Web of Science ®Google Scholar
• BratjburgJElbergSBolardJ1984Interaction of plasma proteins and lipoproteins with amphotericin BJ Infect Dis149986976376657
   PubMed Web of Science ®Google Scholar
• BratjburgJElbergSMedoffJ1985Involvement of oxidative damage in erythrocyte lysis induced by amphotericin BAntimicrob Agents Chemother2717263985601
   PubMed Web of Science ®Google Scholar
• BrezisMRosenPSilvaK1984Polyene toxicity in renal medulla: injury mediated by transport activityScience2246686322305
   PubMed Web of Science ®Google Scholar
• BrittainHG1994Circular dichroism studies of the self-association of Amphotericin BChirality66659
   Web of Science ®Google Scholar
• ChiaJKMcManusEJ1990In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparationsAntimicrob Agents Chemother3490682360827
   PubMed Web of Science ®Google Scholar
• ClemonsKVRanneyDFStevensDA2001A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomesCurr Opin Investig Drugs24807
   PubMedGoogle Scholar
• ClemonsKVEspirituMParmarR2005Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosisAntimicrob Agents Chemother4948677516304147
   PubMed Web of Science ®Google Scholar
• ConoverCDZhaoHLongleyCB2003Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin BBioconjugate Chem146616
   PubMed Web of Science ®Google Scholar
• CornelyO2005AmbiloadAmer Soc HematologyAtlanta, GA
   Google Scholar
• CybulskaBHerveMBorowskiE1986Effects of the polar head structure of polyene macrolide antifungal antibiotics on the mode of permeabilization of ergosterol- and cholsterol-containing lipidic vesicles studied by 31P-NMRMol Pharmacol2929383951434
   PubMed Web of Science ®Google Scholar
• DangiJSVyasSPDixitVK1998Effect of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin B in ratDrug Devel Ind Pharm2463159876507
   PubMed Web of Science ®Google Scholar
• De KruijffBDemelRA1974Polyene antibiotic-sterol interactions in membranes of Acoleplasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyene antibiotic-cholestrol complexesBiochim Biophys Acta33957704546885
   PubMed Web of Science ®Google Scholar
• DelmasGParkSChenZW2002Efficacy of orally delivered co-chleates containing amphotericin B in a murine model of aspergillosisAntimicrob Agents Chemother462704712121962
   PubMed Web of Science ®Google Scholar
• DrewR2006Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infectionsInt J Antimicrob Agents27SS3644
   Web of Science ®Google Scholar
• DromerFBarbetJBolardJ1990Improvement of amphotericin B activity experimental crytococcosis by incorporation into specific immunoliposomesAntimicrob Agents Chemother342055602073097
   PubMed Web of Science ®Google Scholar
• EggimannPGarbinoJPittetD2003Epidemiology of Candida species infections in critically ill non-immunosuppressed patientsLancet Infect Dis368570214592598
   PubMed Web of Science ®Google Scholar
• EllisMSpenceDde PauwB1998An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosisClin Infect Dis271406129868651
   PubMed Web of Science ®Google Scholar
• EgitoESTAppelMFessiH1996aIn-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery systemJ Antimicrob Chemother3848597
   PubMed Web of Science ®Google Scholar
• EgitoESTFessiHAppelM1996bA morphological study of an amphotericin B emulsion-based delivery systemInt J Pharm1451727
   Google Scholar
• Ehrenfreund-KleinmanTAzzamTFalkR2002Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugatesBiomaterials2313273511804288
   PubMed Web of Science ®Google Scholar
• EspuelasMSLegrandPChéronM1998aInteractions of amphotericin B with polymeric colloids. A spectroscopic studyColloids Surfaces B: Biointerfaces1114151
   Web of Science ®Google Scholar
• EspuelasMSLegrandPChéronM1998bInteractions of amphotericin B with polymeric colloids. 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(ɛ-caprolactone) nanospheresColloids Surfaces B: Biointerfaces1120312
   Web of Science ®Google Scholar
• EspuelasMSLegrandPLoiseauPM2000In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188Antimicrob Agents Chemother442190210898700
   PubMed Web of Science ®Google Scholar
• EspuelasMSLegrandPLoiseauPM2002In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nano-spheresJ Drug Target10593812683663
   PubMed Web of Science ®Google Scholar
• EspuelasMSLegrandPCampaneroMA2003Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic miceJ Antimicrob Chemother524192712888593
   PubMed Web of Science ®Google Scholar
• FukuiHKoikeTNakagawaT2003Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commerical lipid-based formulationsInt J Pharm2671011214602388
   PubMed Web of Science ®Google Scholar
• GaboriauFChéronMPetitC1997Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic indexAntimicrob Agents Chemother412345519371331
   PubMed Web of Science ®Google Scholar
• GeorgopapadakouNHWalshTJ1996Antifungal agents: chemotherapeutic targets and immunologic strategiesAntimicrob Agents Chemother40279918834867
   PubMed Web of Science ®Google Scholar
• GradoniLGramicciaMScaloneA2004Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patientsParassitologia4619920115305716
   PubMedGoogle Scholar
• GraybillJRCravenPCTaylorRL1982Treatment of murine Cryptococcus with liposome-associated amphotericin BJ Infect Dis145748527077097
   PubMed Web of Science ®Google Scholar
• GrijalbaMTChéronMBorowskiE2006Modulation of mpolyene antibiotics self-association by ions from the Hofmeister seriesBiochim Biophys Acta1760973916563634
   PubMed Web of Science ®Google Scholar
• GuoLSS2001Amphotericin B colloidal dispersion: an improved anti-fungal therapyAdv Drug Deliv Rev471496311311990
   PubMed Web of Science ®Google Scholar
• HartselSBolardJ1996Amphotericin B: new life for an old drugTIPS1744599014498
   PubMed Web of Science ®Google Scholar
• HartselSCWeilandTR2003Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanismBiochemistry4262283312755626
   PubMed Web of Science ®Google Scholar
• HeathSChanceMLNewRR1984Quantitative and ultrastructural studies on the uptake of drug loaded liposomes by mononuclear phagocytes infected with Leishmania donovani. Mol Biochem Parasitol1249606087139
   PubMed Web of Science ®Google Scholar
• HerbrechtRDenningDWPattersonTF2002Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisN Engl J Med3474081512167683
   PubMed Web of Science ®Google Scholar
• HerbrechtRNatarajan-AmeSNivoixY2003The lipid formulations of amphotericin BExpert Opin Pharmacother412778712877636
   PubMed Web of Science ®Google Scholar
• HerrmannJLDuboisNFourgeaudM1994Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophagesJ Antimicrob Chemother34105187730221
   PubMed Web of Science ®Google Scholar
• HerwaldtBL1999LeishmaniasisLancet541191910513726
   PubMed Web of Science ®Google Scholar
• JanoffASPerkinsWRSaletanSL1993Amphotericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphotericin B-related toxicitesJ Liposome Res345171
   Google Scholar
• JohnsonMDMacDougallCOstrosky-ZeichnerL2004Combination antifungal therapyAntimicrob Agents Chemother4869371514982754
   PubMed Web of Science ®Google Scholar
• Juster-ReicherAFlidel-RimonOAmitayM2003High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonatesEur J Clin Microbiol Infect Dis22603713680398
   PubMed Web of Science ®Google Scholar
• KassabRParrot-LopezHFessiH2002Molecular recognition by Kluyveromyces of amphotericin B-loaded, galactose-targeted, poly(lactic acid) microspheresBioorg Med Chem1017677511937335
   PubMed Web of Science ®Google Scholar
• KayserOOlbrichCYardleyV2003Formulation of amphotericin B as nanosuspension for oral administrationInt J Pharm25473512615413
   PubMed Web of Science ®Google Scholar
• KelseySMGoldmanJMMcCannS1999Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled studyBone Marrow Transplant23163810197802
   PubMed Web of Science ®Google Scholar
• KirkpatrickWRCocoBJPattersonTF2006Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosisAntimicrob Agents Chemother501567916569887
   PubMed Web of Science ®Google Scholar
• KleinbergM2006What is the current and future status of conventional amphotericin B?Int J Antimicrob Agents27SS1216
   Web of Science ®Google Scholar
• KontoyiannisDPHachemRLewisRE2003Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesCancer98292912872348
   PubMed Web of Science ®Google Scholar
• LarabiMLegrandPAppelM2001Reduction of NO synthase expression and TNF alpha production in macrophages by amphotericin B lipid carriersAntimicrob Agents Chemother455536211158754
   PubMed Web of Science ®Google Scholar
• LarabiMYardleyVLoiseauPM2003Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin BAntimicrob Agents Chemother473774914638481
   PubMed Web of Science ®Google Scholar
• LarabiMGulikADedieuJ-P2004aNew lipid formulation of amphotericin B : spectral and microscopic analysisBiochim Biophys Acta16641728115328049
   PubMed Web of Science ®Google Scholar
• LarabiMPagesNPonsF2004Study of the toxicity of a new formulation of amphotericin BJ Antimicrob Chemother5381814657087
   PubMed Web of Science ®Google Scholar
• LeendersACReissPPortegiesP1997Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitisAids111463719342068
   PubMed Web of Science ®Google Scholar
• LeendersACDaenenSJansenRL1998Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infectionsBr J Haematol103205129792309
   PubMed Web of Science ®Google Scholar
• LegrandPVertut-DoïABolardJ1996Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell lineJ Antimicrob Chemother37519339182109
   PubMed Web of Science ®Google Scholar
• LincopanNMamizukaEMCarmona-RibeiroAM2005Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragmentsJ Antimicrob Chemother557273415761070
   PubMed Web of Science ®Google Scholar
• LincopanNBorelliPFockR2006Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratioExp Toxicol Pathol581758316982179
   PubMedGoogle Scholar
• Lopez-BeresteinGMehtaRHopferR1983Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasisCancer Drug Deliv137426544116
   PubMedGoogle Scholar
• MaertensJVrebosMBoogaertsM2001Assessing risk factors for systemic fungal infectionsEur J Cancer Care (Engl)10566211827268
   PubMed Web of Science ®Google Scholar
• MangéANishidaNMilhavetO2000Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected culturesVirology74313540
   Web of Science ®Google Scholar
• MarrKABoeckhMCarterRA2004Combination antifungal therapy for invasive aspergillosisClin Infect Dis3979780215472810
   PubMed Web of Science ®Google Scholar
• MazerskiJBolardJBorowskiE1982Self association of some polyene macrolide antibiotics in aqueous mediaBiochim Biophys Acta7191117
   Web of Science ®Google Scholar
• MehtaPVinksAFilipovichA2006High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyBiol Blood Marrow Transplant122354016443521
   PubMed Web of Science ®Google Scholar
• MénezCBuyseMChacunH2006aModulation of intestinal barrier properties by miltefosineBiochem Pharmacol7148696
   PubMed Web of Science ®Google Scholar
• MénezCBuyseMBesnardM2006bInteraction between miltefosine and amphotericin B: consequences for their activity towards intestinal epithelial cells and L. donovani promastigotes in vitroAntimicrob Agents Chemother503793800
   PubMed Web of Science ®Google Scholar
• MercadalMDomingoJCPetrizJC1999A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface grafted PEG chainsBiochim Biophys Acta1418232810209227
   PubMed Web of Science ®Google Scholar
• MeyerhoffA1999U.S. Food and Drug Administration approval of AmBi-some (liposomal amphotericin B) for treatment of visceral leishmaniasisClin Infect Dis28428 discussion 49–5110028069
   PubMed Web of Science ®Google Scholar
• MozaffarianNBermanJWCasadevallA1997Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin BAntimicrob Agents Chemother41182599257771
   PubMed Web of Science ®Google Scholar
• MüllerRHSchmidtSButtleI2004SolEmuls® - novel technology for the formulation of i.v. emulsions with poorly soluble drugsInt J Pharm26929330214706241
   PubMed Web of Science ®Google Scholar
• MurrayHW2001Clinical and experimental advances in treatment of visceral leishmaniasisAntimicrob Agents Chemother4521859711451673
   PubMed Web of Science ®Google Scholar
• MurrayHW2004Progress in the treatment of a neglected infectious disease: visceral leishmaniasisExpert Rev Anti-infect Ther22799215482193
   PubMedGoogle Scholar
• NelsonKGBishopJVRyanRO2006Nanodisk-associated amphotericin B clears Leishmania major cutaneous infections in susceptible BALB/c miceAntimicrob Agents Chemother5012384416569834
   PubMed Web of Science ®Google Scholar
• NewRRChanceMLHeathS1981Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomesJ Antimicrob Chemother8371817319979
   PubMed Web of Science ®Google Scholar
• OdaMNHargreavesPLBecksteadJA2006Reconstituted high-density lipoprotein enriched with the polyene antibiotic amphotericin BJ Lipid Res472607 errata p 111416314670
   PubMed Web of Science ®Google Scholar
• OlsonJAAdler-MooreJPSmithPJ2005Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafunginAntimicrob Agents Chemother49489590216304150
   PubMed Web of Science ®Google Scholar
• OtsuboTMaruyamaKMaesakiS1998Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in miceAntimicrob Agents Chemother424049449258
   PubMed Web of Science ®Google Scholar
• PappasPGRexJHLeeJ2003A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patientsClin Infect Dis376344312942393
   PubMed Web of Science ®Google Scholar
• PerfectJRDodds AshleyEDrewR2004Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipientsClin Infect Dis39Suppl 4S2071015546119
   PubMed Web of Science ®Google Scholar
• PolakA1999The past, present and future of antimycotic combination therapyMycoses423557010536428
   PubMed Web of Science ®Google Scholar
• PrenticeHGHannIMHerbrechtR1997A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsBr J Haematol98711189332329
   PubMed Web of Science ®Google Scholar
• Rama IniguezSDea-AyuelaMASánchez-BruneteJA2006Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulationAntimicrob Agents Chemother50119520116569829
   PubMed Web of Science ®Google Scholar
• RingdenOMeunierFTollemarJ1991Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patientsJ Antimicrob Chemother28Suppl B73821778894
   PubMed Web of Science ®Google Scholar
• RisovicVSachs-BarrableKBoydM2004Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin BDrug Dev Ind Pharm307677415491054
   PubMed Web of Science ®Google Scholar
• RuijgrokRJFensMHBakker-WoudenbergIA2005Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence of long-term biological activityJ Pharm Pharmacol5712899516259757
   PubMed Web of Science ®Google Scholar
• Sánchez-BruneteJADeaMARamaS2004Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheresAntimicrob Agents Chemother4832465215328080
   PubMed Web of Science ®Google Scholar
• Sánchez-BruneteJADeaMARamaS2005Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin BJ Drug Target132253316051534
   PubMed Web of Science ®Google Scholar
• SantangeloRPaderuPDelmasG2000Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasisAntimicrob Agents Chemother4423566010952579
   PubMed Web of Science ®Google Scholar
• SeifertKCroftSL2006In vitro and in vivo interactions between miltefosine and other antileishmanial drugsAntimicrob Agents Chemother5073916377670
   PubMed Web of Science ®Google Scholar
• SinghSSivakumarR2004Challenges and new discoveries in the treatment of leishmaniasisJ Infect Chemother103071515614453
   PubMedGoogle Scholar
• Sokolsky-PapkovMDombAJGolenserJ2006Impact of aldehyde content on amphotericin B-dextran imine conjugate toxicityBiomacromolecules715293516677035
   PubMed Web of Science ®Google Scholar
• SundarSMehtaHSureshAV2004Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulationsClin Infect Dis383778314727208
   PubMed Web of Science ®Google Scholar
• SzokaFCMilhollandDBarzaM1987Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin BAntimicrob Agents Chemother3142193579259
   PubMed Web of Science ®Google Scholar
• TaylorRLWilliamsDMCravenPC1982Amphotericin B in liposomes: a novel therapy for histoplasmosisAm Rev Respir Dis125610117081822
   PubMed Web of Science ®Google Scholar
• TiyaboonchaiWLimpeanchobN2006Formulation and characterization of amphotericin B-chitosan-dextran sulphate nanoparticlesInt J Pharm doi:10.1016/j.ijpharm.2006.08.013
   Google Scholar
• TollemarJRingdenOAnderssonS1993aRandomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipientsBone Marrow Transplant12577828136741
   PubMed Web of Science ®Google Scholar
• TollemarJRingdenOAnderssonS1993bProphylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipientsTransplant Proc25149578442163
   PubMed Web of Science ®Google Scholar
• TollemarJHockerstedtKEriczonBG1995Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trialTransplant Proc27119587878847
   PubMed Web of Science ®Google Scholar
• TokudaYTsujiMYamazakiM1993Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivoAntimicrob Agents Chemother372228308257149
   PubMed Web of Science ®Google Scholar
• TomiiY2002Lipid formulation as a drug carrier for drug deliveryCurr Pharmaceut Design846774
   PubMed Web of Science ®Google Scholar
• UtzJPTregerAMcCulloughNB1958–1959Amphotericin B: intravenous use in 21 patients with systemic fungal diseasesAntibiot Annu1958195962834
   Google Scholar
• Van EttenEWMVan VianenWRooversP2000Mild heating of Amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic miceAntimicrob Agents Chemother44159860310817715
   PubMed Web of Science ®Google Scholar
• VanderputteJWachtelJLStillerET1955–1956Amphotericins A and B, antifungal antibiotics produced by a streptomycete. II The isolation and properties of the crystalline amphotericinsAntibiot Annu1955195658791
   Google Scholar
• VandermeulenGRouxhetLArienA2006Encapsulation of amphotericin B in poly(ethylene glycol) -block-poly(e-caprolactone-co-tri-methylenecarbonate) polymeric micellesInt J Pharm3092344016406402
   PubMed Web of Science ®Google Scholar
• Venier-JulienneMCVouldoukisIMonjourL1995In vitro study of the anti-leishmanial activity of biodegradable nanoparticlesJ Drug Target32397655817
   PubMed Web of Science ®Google Scholar
• VyasSPKatareYKMishraV2000Ligand directed macrophage targeting of amphotericin B loaded liposomesInt J Pharm21011411163983
   PubMed Web of Science ®Google Scholar
• VyasSPQuraishiSGuptaS2005Aerosolized liposome-based delivery of amphotericin B to alveolar macrophagesInt J Pharm296122515885451
   PubMed Web of Science ®Google Scholar
• WalshTJFinbergRWArndtC1999Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study GroupN Engl J Med3407647110072411
   PubMed Web of Science ®Google Scholar
• WalshTJGoodmanJLPappasP2001Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose studyAntimicrob Agents Chemother4534879611709329
   PubMed Web of Science ®Google Scholar
• WilsonEThorsonLSpeertDP1991Enhancement of macrophage superoxide anion production by amphotericin BAntimicrob Agents Chemother357968001649568
   PubMed Web of Science ®Google Scholar
• WingardJRWhiteMHAnaissieE2000A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study GroupClin Infect Dis3111556311073745
   PubMed Web of Science ®Google Scholar
• WuWWieckowskiSPastorinG2005Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubesAngew Chem Int Ed44635862
   PubMed Web of Science ®Google Scholar
• YardleyVCroftSL2000A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasisInt J Antimicrob Agents13243810755238
   PubMed Web of Science ®Google Scholar
• YooBKJalil MiahMALeeE-S2006Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acidBiol Pharm Bull291700516880628
   PubMed Web of Science ®Google Scholar
• ZarifL2005Drug delivery by lipid cochleatesMeth Enzymol3913142915721389
   PubMed Web of Science ®Google Scholar
• ZhangXXieJLiS2003The study on brain targeting of the amphotericin B liposomesJ Drug Target111172212881198
   PubMed Web of Science ®Google Scholar